Affiliation:
1. Ageing and Pharmacology Laboratory, Kolling Institute, Faculty of Medicine and Health The University of Sydney and the Northern Sydney Local Health District Sydney Australia
2. Aged Care Department Royal North Shore Hospital Sydney Australia
3. St George and Sutherland Clinical School, Faculty of Medicine University of New South Wales Sydney Australia
4. Department of Geriatric Medicine and Centre for Education and Research on Ageing Concord Hospital Sydney Australia
5. Concord Clinical School, Faculty of Medicine and Health The University of Sydney Sydney Australia
6. School of Pharmacy, Faculty of Medicine and Health The University of Sydney Sydney Australia
7. Clinical Pharmacology Department Royal North Shore Hospital Sydney Australia
Abstract
AbstractBackgroundThe Drug Burden Index (DBI) measures an individual's total exposure to anticholinergic and sedative medications. This systematic review aimed to investigate the association of the DBI with clinical and prescribing outcomes in observational pharmaco‐epidemiological studies, and the effect of DBI exposure on functional outcomes in pre‐clinical models.MethodsA systematic search of nine electronic databases, citation indexes and gray literature was performed (April 1, 2007–December 31, 2022). Studies that reported primary data on the association of the DBI with clinical or prescribing outcomes conducted in any setting in humans aged ≥18 years or animals were included. Quality assessment was performed using the Joanna Briggs Institute critical appraisal tools and the Systematic Review Centre for Laboratory animal Experimentation risk of bias tool.ResultsOf 2382 studies screened, 70 met the inclusion criteria (65 in humans, five in animals). In humans, outcomes reported included function (n = 56), cognition (n = 20), falls (n = 14), frailty (n = 7), mortality (n = 9), quality of life (n = 8), hospitalization (n = 7), length of stay (n = 5), readmission (n = 1), other clinical outcomes (n = 15) and prescribing outcomes (n = 2). A higher DBI was significantly associated with increased falls (11/14, 71%), poorer function (31/56, 55%), and cognition (11/20, 55%) related outcomes. Narrative synthesis was used due to significant heterogeneity in the study population, setting, study type, definition of DBI, and outcome measures. Results could not be pooled due to heterogeneity. In animals, outcomes reported included function (n = 18), frailty (n = 2), and mortality (n = 1). In pre‐clinical studies, a higher DBI caused poorer function and frailty.ConclusionsA higher DBI may be associated with an increased risk of falls and decreased function and cognition. Higher DBI was inconsistently associated with increased mortality, length of stay, frailty, hospitalization or reduced quality of life. Human observational findings with respect to functional outcomes are supported by preclinical interventional studies. The DBI may be used as a tool to identify older adults at higher risk of harm.
Subject
Geriatrics and Gerontology